Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors

Genitourinary CancerLung, Respiratory and Thoracic CancerSkin Cancer

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Int J Radiat Oncol Biol Phys.

Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, Brahmer J, Lipson E, Sharfman W, Hammers H, Naidoo J, Bettegowda C, Lim M, Redmond KJ

doi: 10.1016/j.ijrobp.2017.11.041.

Further Publications

Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors

Eur J Cancer.

Maillet D, Corbaux P, Stelmes JJ, Dalle S, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Freyer G, Boespflug A, Péron J

doi: 10.1016/j.ejca.2020.03.017.

Skin Cancer

The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study

J Neurooncol.

Martins F, Schiappacasse L, Levivier M, Tuleasca C, Cuendet MA, Aedo-Lopez V, Gautron Moura B, Homicsko K, Bettini A, Berthod G, Gérard CL, Wicky A, Bourhis J, Michielin O

doi: 10.1007/s11060-019-03363-0.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Outcome of non-small cell lung cancer patients with brain metastases treated with checkpoint inhibitors

J Thorac Oncol.

Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, de Ruysscher D, Dingemans AM, Besse B

doi: 10.1016/j.jtho.2019.02.009.

Further Publications

Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study

Eur J Cancer

Da Silva Lopes AM, Colomer-Lahiguera S, Mederos Alfonso N, Aedo-Lopez V, Spurrier-Bernard G, Tolstrup LK, Pappot H, Aspeslagh S, Rogiers A, Neyns B, Haanen JB, Mitchell SA, Addeo A, Michielin O, Eicher M

doi: 10.1016/j.ejca.2021.08.026

Skin Cancer

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

Eur J Cancer.

Bastholt L, Schmidt H, Bjerregaard JK, Herrstedt J, Svane IM

doi: 10.1016/j.ejca.2019.06.022.

Skin Cancer

Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitors refractory advanced melanoma

Melanoma Res.

Seremet T, Planken S, Schwarze JK, Jansen Y, Vandeweerd L, van den Begin R, Tsechelidis I, Lienard D, Del Marmol V, Neyns B

doi: 10.1097/

Central Nervous System Tumors

Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases

Eur J Cancer

Hilbers ML, Dimitriou F, Lau P, Bhave P, McArthur GA, Zimmer L, Kudura K, Gérard CL, Levesque MP, Michielin O, Dummer R, Cheng PF, Mangana J

doi: 10.1016/j.ejca.2021.07.028

Central Nervous System Tumors

Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases

Eur J Cancer

Hilbers ML, Dimitriou F, Lau P, Bhave P, McArthur GA, Zimmer L, Kudura K, Gérard CL, Levesque MP, Michielin O, Dummer R, Cheng PF, Mangana J

doi: 10.1016/j.ejca.2021.07.028

Related content

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors

The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study

Outcome of non-small cell lung cancer patients with brain metastases treated with checkpoint inhibitors

Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitors refractory advanced melanoma

Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases

Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases